Age [years] |
14.8 (3.7-18.0) |
Boys/girls (n/n) (%/%) |
22/11 (66.7% / 33.3%) |
Renal disease (n) (%):
Henoch-Schonlein nephropathy
IgA nephropathy
Membranoproliferative glomerulonephritis
Minimal change disease
Focal segmental glomerulosclerosis
Mesangioproliferative glomerulonephritis
Other |
9 (27.3%)
7 (21.2%)
4 (12.1%)
3 (9.1%)
3 (9.1%)
3 (9.1%)
4 (12.1%) |
Presence of hypertension (n) (%) |
13 (39.4%) |
Age at the onset of renal disease [years] |
7.9 (0.3-16.0) |
Duration of renal disease [months] |
31.0 (1.0-155.0) |
Age at the onset of hypertension [years] |
9.0 (0.3-17.5) |
Duration of hypertension [months] |
19.0 (1.0-144.0) |
BMI Z- score |
0.3 ± 1.3 |
Creatinine [mg/dL] |
0.6 (0.3-10.1) |
Urea [mg/dL] |
25.0 (10.0-131.9) |
Uric acid [mg/dL] |
5.9 ± 2.0 |
GFR by Schwartz formula [mL/min/1.73m2] |
110.3 (20.8-166.6) |
Total protein [g/dL] |
6.8 (3.4-8.1) |
Albumin [g/dL] |
3.8 (1.5 – 4.9) |
Total cholesterol [mg/dL] |
212.8 ± 60.3 |
Triglycerides [mg/dL] |
139.6 ± 53.5 |
Calcium [mg/dL] |
9.5 ± 0.6 |
Proteinuria [mg/kg/24h] n=15 (45.5%) |
50.5 (4.5-322.1) |
Immunosuppressive therapy |
Prednisone (n) (%)
Prednisone dose [mg/kg/24h]
Cyclosporin A (n) (%)
Azathioprine (n) (%)
Mycophenolate mofetil (n) (%) |
23 (70.0%)
0.62 (0.03-1.43)
5 (15.1%)
3 (9.1%)
2 (6.0%) |
Antihypertensive treatment |
Enalapril (n) (%)
Enalapril dose [mg/kg/24h]
Losartan (n) (%)
Amlodypine (n) (%) |
21 (66.7%)
0.11 (0.04-0.21)
5 (15.2%)
6 (18.2%) |
BMI: Body Mass Index; GFR: Glomerular Filtration Rate.